Common Light Chain Antibody

Following the success of Akesobio and Kelun Innovations, which collectively achieved over 10 billion USD in antibody drug licensing, more good news has arrived at the beginning of the new year regarding domestic pharmaceutical companies licensing novel antibody drug molecule. Among these, Hengrui Pharmaceuticals, CSPC, and WuXi AppTec have all successfully licensed new drug molecules to overseas entities. GSK and WuXi AppTec have reached a licensing agreement. GSK will obtain exclusive rights to up to 4 TCE bispecific antibodies/multispecific antibodies developed based on WuXi AppTec’s patented technology platform. For this, GSK will pay 1.5 billion US dollars (10.1 billion RMB) and a certain sales share. WuXi AppTec’s TCE bispecific antibodies target tumor-associated antigens (TAA) present on the surface of tumor cells and CD3 antigens found on the surface of T cells. By binding to both tumor cells and T cells, these antibodies trigger specific activation of T cells, enabling them to efficiently eliminate tumor cells. The concept of bispecific antibodies (BsAbs) was first introduced by A. Nisonoff and colleagues in 1960. Based on differences in molecular structure, BsAbs can be classified into two main categories: those based on antibody fragments and those based on Fc domains. BsAbs offer a unique combination of advantages, including increased effectiveness and reduced toxicity when compared to monoclonal antibodies. Furthermore, they can mediate a range of specific biological effects, such as cell bridging, dual-target blockade, and the formation of protein complexes.